- Response to Secukinumab had accelerated over time: Responseappeared after 2 weeks (poor: 2%, fair: 72%), was prominent after 4 weeks (good: 82%, fair: 18%), after 8 weeks (very good: 42%, good: 58%), after 8 weeks (very good: 90%, good: 10%) and patients were free of lesions after 24 weeks.